Roche Holding AG Total Long Term Liabilities 2012-2025 | RHHBY
Roche Holding AG total long term liabilities from 2012 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.
- Roche Holding AG total long term liabilities for the quarter ending December 31, 2025 were $42.030B, a 35.82% increase year-over-year.
- Roche Holding AG total long term liabilities for 2025 were $42.03B, a 4.18% decline from 2024.
- Roche Holding AG total long term liabilities for 2024 were $43.865B, a 21.61% increase from 2023.
- Roche Holding AG total long term liabilities for 2023 were $36.069B, a 19.11% increase from 2022.
|
Roche Holding AG Annual Total Long Term Liabilities (Millions of US $) |
|
|---|---|
| 2025 | $42,030 |
| 2024 | $43,865 |
| 2023 | $36,069 |
| 2022 | $30,281 |
| 2021 | $27,961 |
| 2020 | $22,360 |
| 2019 | $23,255 |
| 2018 | $25,681 |
| 2017 | $25,925 |
| 2016 | $28,243 |
| 2015 | $29,863 |
| 2014 | $33,896 |
| 2013 | $27,167 |
| 2012 | $29,738 |
| 2011 | $34,970 |
|
Roche Holding AG Quarterly Total Long Term Liabilities (Millions of US $) |
|
|---|---|
| 2025-12-31 | $42,030 |
| 2024-12-31 | $43,865 |
| 2024-06-30 | $40,149 |
| 2023-12-31 | $36,069 |
| 2023-06-30 | $30,945 |
| 2022-12-31 | $30,281 |
| 2022-06-30 | $31,463 |
| 2021-12-31 | $27,961 |
| 2021-06-30 | $22,677 |
| 2020-12-31 | $22,360 |
| 2020-06-30 | $23,955 |
| 2019-12-31 | $23,255 |
| 2019-06-30 | $25,675 |
| 2018-12-31 | $25,681 |
| 2018-06-30 | $25,357 |
| 2017-12-31 | $25,925 |
| 2017-06-30 | $26,364 |
| 2016-12-31 | $28,243 |
| 2016-06-30 | $29,864 |
| 2015-12-31 | $29,863 |
| 2015-06-30 | $29,728 |
| 2014-12-31 | $33,896 |
| 2014-06-30 | $27,674 |
| 2013-12-31 | $27,167 |
| 2013-06-30 | $28,799 |
| 2012-12-31 | $29,738 |
| 2012-06-30 | $31,586 |
| 2011-12-31 | $34,970 |
| 2011-06-30 | $33,405 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $318.782B | $76.450B |
| Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |